MMCM
NTLA icon

Murphy & Mullick Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Murphy & Mullick Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.14K Sell
167
-11
-6% -$140 ﹤0.01% 597
2025
Q4 		$1.6K Hold
178
– – ﹤0.01% 617
2025
Q3 		$3.07K Sell
178
-29
-14% -$357 ﹤0.01% 573
2025
Q2 		$2.41K Sell
207
-58
-22% -$476 ﹤0.01% 574
2025
Q1 		$1.88K Hold
265
– – ﹤0.01% 574
2024
Q4 		$3.09K Buy
+265
New +$4.14K ﹤0.01% 537

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Murphy & Mullick Capital Management's NTLA Position: Q1 2026 in Review

Murphy & Mullick Capital Management reduced its Intellia Therapeutics (NTLA) stake by 6.2% in Q1 2026, selling an estimated $140 and leaving 167 shares worth $2.14K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

Murphy & Mullick Capital Management first reported a position in NTLA in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.09K in Q4 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Murphy & Mullick Capital Management held 167 shares of Intellia Therapeutics worth $2.14K as of Q1 2026.
  • Murphy & Mullick Capital Management sold 11 Intellia Therapeutics shares in Q1 2026, an estimated $140.
  • Intellia Therapeutics made up ﹤0.01% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #597 holding.
  • Murphy & Mullick Capital Management first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Murphy & Mullick Capital Management's Intellia Therapeutics position peaked at $3.09K in Q4 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.